European Journal of Chemistry

Theoretical investigation of a few selected compounds as potent anti-tubercular agents and molecular docking evaluation: A multi-linear regression approach

Crossmark


Main Article Content

Shola Elijah Adeniji
Abdulwahab Isiaka
Kalen Ephraim Audu
Olajumoke Bosede Adalumo

Abstract

Emergence of multi-drug resistant strains of Mycobacterium tuberculosis to the available drugs has demanded for the development of more potent anti-tubercular agents with efficient pharmacological activities. Time consumed and expenses in discovering and synthesizing new drug targets with improved biological activity have been a major challenge toward the treatment of multi-drug resistance strain M. tuberculosis. To solve the above problem, Quantitative Structure Activity Relationship (QSAR) is a recent approach developed to discover a novel drug with a better biological against M. Tuberculosis. A validated QSAR model developed in this study to predict the biological activities of some anti-tubercular compounds and to design new hypothetical drugs is influenced with the molecular descriptors; AATS7s, VR1-Dzi, VR1-Dzs, SpMin7-Bhe and RDF110i. The internal validation test for the derived model was found to have correlation coefficient (R2) of 0.8875, adjusted correlation coefficient (R2adj) value of 0.8234 and leave one out cross validation coefficient (Qcv2) value of 0.8012 while the external validation test was found to have (R2test) of 0.7961 and Y-randomization Coefficient (cRp2) of 0.6832. Molecular docking shows that ligand 13 of 2,4-disubstituted quinoline derivatives have promising higher binding score of -18.8 kcal/mol compared to the recommended drugs; isoniazid -14.6 kcal/mol. The proposed QSAR model and molecular docking studies will provides valuable approach for the modification of the lead compound, designing and synthesis more potent anti-tubercular agents.


icon graph This Abstract was viewed 1583 times | icon graph Article PDF downloaded 484 times

How to Cite
(1)
Adeniji, S. E.; Isiaka, A.; Audu, K. E.; Adalumo, O. B. Theoretical Investigation of a Few Selected Compounds As Potent Anti-Tubercular Agents and Molecular Docking Evaluation: A Multi-Linear Regression Approach. Eur. J. Chem. 2020, 11, 60-67.

Article Details

Share
Crossref - Scopus - Google - European PMC
References

[1]. World Health Organization, Tuberculosis, Retrieved Feb 01, 2020, from http://www.who.int/news-room/fact-sheets/detail/ tuberculosis.

[2]. Hansch, C.; Kurup, A.; Garg, R.; Gao, H. Chem. Rev. 2001, 101, 619-672.
https://doi.org/10.1021/cr0000067

[3]. Adeniji, S. E.; Uba, S.; Uzairu, A. J. Pathog. 2018, 1018694.
https://doi.org/10.1155/2018/1018694

[4]. Ogadimma, A. I.; Adamu, U. Open Access Lib. J. 2016, 3, 1-13.
https://doi.org/10.4236/oalib.1102432

[5]. Eric, G. M.; Uzairu, A.; Mamza, P. A. J. Sci. Res. Rep. 2016, 10, 1-15.
https://doi.org/10.9734/JSRR/2016/23176

[6]. Adeniji, S. E.; Uba, S.; Uzairu, A. Phys. Chem. Res. 2018, 6, 479-492.
https://doi.org/10.1155/2018/1018694

[7]. Adeniji, S. E.; Uba, S.; Uzairu, A. J. King Saud University-Sci. 2020, 32(1), 67-74.
https://doi.org/10.1016/j.jksus.2018.02.005

[8]. Nayyar, A.; Jain, R. Indian J. Chem. B 2008, 47, 117-128.

[9]. Yap, C. W. J. Comput. Chem. 2011, 32, 1466-1474.
https://doi.org/10.1002/jcc.21707

[10]. Singh, P. J. Curr. Chem. Pharm. Sci. 2013, 3(1), 64-79.

[11]. Adeniji, S. E.; Uba, S.; Uzairu, A.; Arthur, D. E. Adv. Preventive Med. 2019, 5173786, 1-18.
https://doi.org/10.1155/2019/5173786

[12]. Tropsha, A.; Gramatica, P.; Gombar, V. K. Mol. Inform. 2003, 22, 69-77.
https://doi.org/10.1002/qsar.200390007

[13]. Roy, K.; Chakraborty, P.; Mitra, I.; Ojha, P. K.; Kar, S.; Das, R. N. J. Comput. Chem. 2013, 34, 1071-1082.
https://doi.org/10.1002/jcc.23231

[14]. Veerasamy, R.; Rajak, H.; Jain, A.; Sivadasan, S.; Varghese, C. P.; Agrawal, R. K. Int. J. Drug Des. Discover. 2011, 2(3), 511-519.

[15]. Adeniji, S. E.; Uba, S.; Uzairu, A. Netw. Model. Anal. Health Inform. Bioinforma. 2020, 9(8), 1-18.
https://doi.org/10.1007/s13721-019-0212-6

[16]. Piton, J.; Petrella, S.; Delarue, M.; Andre-Leroux, G.; Jarlier, V.; Aubry, A.; Mayer, C. Retrieved Feb 01, 2020, from https://www. rcsb. org/structure/3IFZ

[17]. Adeniji, S. E.; Uba, S.; Uzairu, A. Future. J. Pharm. Sci. 2018, 4, 284-295.
https://doi.org/10.1016/j.fjps.2018.10.003

Most read articles by the same author(s)
TrendMD

Dimensions - Altmetric - scite_ - PlumX

Downloads and views

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
License Terms

License Terms

by-nc

Copyright © 2024 by Authors. This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at https://www.eurjchem.com/index.php/eurjchem/terms and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution, or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (https://www.eurjchem.com/index.php/eurjchem/terms) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).